Key Takeaways Expansion into rare kidney diseases and strong leadership in eye disease treatments set the stage for revenue growth and increased market reach. Enhanced balance sheet and operational efficiency enable greater investment in R&D and commercialization, supporting profitability and long-term earnings potential.Read more
Key Takeaways EMPAVELI and SYFOVRE are positioned to capture dominant market shares and drive sustained revenue growth through broad adoption and durable clinical efficacy. Advances in pipeline therapies and operational discipline strengthen both profit margins and long-term earnings leverage, setting Apellis apart from industry peers.Read more
Key Takeaways Heavy reliance on two core products and high R&D costs leave Apellis vulnerable to shifting market forces and uncertain pipeline outcomes. Growing regulatory challenges, reimbursement limits, and rising competition threaten revenue growth, market share, and the company's long-term profitability prospects.Read more
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
